Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: October 6, 2022

Details for Patent: 9,271,931

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,271,931 protect, and when does it expire?

Patent 9,271,931 protects VYXEOS and is included in one NDA.

This patent has forty-five patent family members in thirteen countries.

Summary for Patent: 9,271,931
Title:Compositions for delivery of drug combinations
Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
Inventor(s): Tardi; Paul (Surrey, CA), Harasym; Troy (North Vancouver, CA), Webb; Murray (North Vancouver, CA), Shew; Clifford (Vancouver, CA), Janoff; Andrew (Yardley, PA), Bally; Marcel (Bowen Island, CA)
Application Number:10/553,373
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,271,931
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Dosage form;

Drugs Protected by US Patent 9,271,931

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,271,931

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada2383259Apr 23, 2002
PCT Information
PCT FiledApril 16, 2004PCT Application Number:PCT/US2004/011812
PCT Publication Date:November 04, 2004PCT Publication Number: WO2004/093795

International Family Members for US Patent 9,271,931

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 345775 See Plans and Pricing
Austria 475411 See Plans and Pricing
Australia 2002331480 See Plans and Pricing
Australia 2002331481 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.